Bougnoux P - Search Results

1

Tumor parameters, clinical and pathological responses, medical management, and survival through time on 710 operable breast cancers.

Abrial C, Mouret-Reynier MA, Amat S, Sillet-Bach I, Bougnoux P, Delva R, Cure H, Dauplat J, Penault-Llorca F, Chollet P. Abrial C, et al. Among authors: bougnoux p. Med Oncol. 2005;22(3):233-40. doi: 10.1385/MO:22:3:233. Med Oncol. 2005. PMID: 16110134

2

Neoadjuvant docetaxel for operable breast cancer induces a high pathological response and breast-conservation rate.

Amat S, Bougnoux P, Penault-Llorca F, Fétissof F, Curé H, Kwiatkowski F, Achard JL, Body G, Dauplat J, Chollet P. Amat S, et al. Among authors: bougnoux p. Br J Cancer. 2003 May 6;88(9):1339-45. doi: 10.1038/sj.bjc.6600916. Br J Cancer. 2003. PMID: 12778058 Free PMC article. Clinical Trial.

3

High prognostic significance of residual disease after neoadjuvant chemotherapy: a retrospective study in 710 patients with operable breast cancer.

Abrial SC, Penault-Llorca F, Delva R, Bougnoux P, Leduc B, Mouret-Reynier MA, Mery-Mignard D, Bleuse JP, Dauplat J, Curé H, Chollet P. Abrial SC, et al. Among authors: bougnoux p. Breast Cancer Res Treat. 2005 Dec;94(3):255-63. doi: 10.1007/s10549-005-9008-8. Breast Cancer Res Treat. 2005. PMID: 16267618

4

Use of [(18)F]-FDG PET to predict response to neoadjuvant trastuzumab and docetaxel in patients with HER2-positive breast cancer, and addition of bevacizumab to neoadjuvant trastuzumab and docetaxel in [(18)F]-FDG PET-predicted non-responders (AVATAXHER): an open-label, randomised phase 2 trial.

Coudert B, Pierga JY, Mouret-Reynier MA, Kerrou K, Ferrero JM, Petit T, Kerbrat P, Dupré PF, Bachelot T, Gabelle P, Giard S, Coeffic D, Bougnoux P, Prevost JB, Paintaud G, Thibault G, Hernandez J, Coudert M, Arnould L, Berriolo-Riedinger A. Coudert B, et al. Among authors: bougnoux p. Lancet Oncol. 2014 Dec;15(13):1493-1502. doi: 10.1016/S1470-2045(14)70475-9. Epub 2014 Oct 30. Lancet Oncol. 2014. PMID: 25456368 Clinical Trial.

5

A phase II study of a paclitaxel and oxaliplatin combination in platinum-sensitive recurrent advanced ovarian cancer patients.

Viens P, Petit T, Yovine A, Bougnoux P, Deplanque G, Cottu PH, Delva R, Lotz JP, Belle SV, Extra JM, Cvitkovic E. Viens P, et al. Among authors: bougnoux p. Ann Oncol. 2006 Mar;17(3):429-36. doi: 10.1093/annonc/mdj097. Ann Oncol. 2006. PMID: 16500913 Free article. Clinical Trial.

6

Multicentre phase II study of oxaliplatin as a single-agent in cisplatin/carboplatin +/- taxane-pretreated ovarian cancer patients.

Dieras V, Bougnoux P, Petit T, Chollet P, Beuzeboc P, Borel C, Husseini F, Goupil A, Kerbrat P, Misset JL, Bensmaïne MA, Tabah-Fisch I, Pouillart P. Dieras V, et al. Among authors: bougnoux p. Ann Oncol. 2002 Feb;13(2):258-66. doi: 10.1093/annonc/mdf018. Ann Oncol. 2002. PMID: 11886003 Free article. Clinical Trial.

7

Results of ZD0473 in platinum-pretreated ovarian cancer: analysis according to platinum free interval.

Gore ME, Atkinson RJ, Thomas H, Cure H, Rischin D, Beale P, Bougnoux P, Dirix L, Smit WM. Gore ME, et al. Among authors: bougnoux p. Eur J Cancer. 2002 Dec;38 Suppl 8:S7-12. doi: 10.1016/s0959-8049(02)80014-4. Eur J Cancer. 2002. PMID: 12645907 Clinical Trial.

8

Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study.

Cortes J, O'Shaughnessy J, Loesch D, Blum JL, Vahdat LT, Petrakova K, Chollet P, Manikas A, Diéras V, Delozier T, Vladimirov V, Cardoso F, Koh H, Bougnoux P, Dutcus CE, Seegobin S, Mir D, Meneses N, Wanders J, Twelves C; EMBRACE (Eisai Metastatic Breast Cancer Study Assessing Physician's Choice Versus E7389) investigators. Cortes J, et al. Among authors: bougnoux p. Lancet. 2011 Mar 12;377(9769):914-23. doi: 10.1016/S0140-6736(11)60070-6. Epub 2011 Mar 2. Lancet. 2011. PMID: 21376385 Clinical Trial.

9

Primary chemotherapy and radiosurgical breast-conserving treatment for patients with locally advanced operable breast cancers.

Calais G, Descamps P, Chapet S, Turgeon V, Reynaud-Bougnoux A, Lemarié E, Fignon A, Body G, Bougnoux P, Lansac J, et al. Calais G, et al. Among authors: bougnoux p. Int J Radiat Oncol Biol Phys. 1993 Apr 30;26(1):37-42. doi: 10.1016/0360-3016(93)90170-z. Int J Radiat Oncol Biol Phys. 1993. PMID: 8387066

10

A phase II trial of ZD0473 in platinum-pretreated ovarian cancer.

Gore ME, Atkinson RJ, Thomas H, Cure H, Rischin D, Beale P, Bougnoux P, Dirix L, Smit WM. Gore ME, et al. Among authors: bougnoux p. Eur J Cancer. 2002 Dec;38(18):2416-20. doi: 10.1016/s0959-8049(02)00632-9. Eur J Cancer. 2002. PMID: 12460786 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

159 results

Search Page

Filters